Invisible After 30: The Hidden Women's Healthcare Crisis

When Halle Berry was 54, she fell in love. She'd started dating the musician Van Hunt, and things were going well. Then one morning, after they'd been intimate, she tried to go to the bathroom and couldn't. "It was so painful when I tried to let a little bit out," she later recalled on The Drew Barrymore Show. "It took me almost 10 minutes just to empty my bladder." She was so swollen she couldn't put her legs together to drive.¹

She went to her doctor. After examining her, he delivered his diagnosis: "You have the worst case of herpes I've ever seen."¹

Berry and Hunt spent the next 72 hours in anguish, trying to figure out who had given it to whom. Then the doctor called back. Neither of them had herpes. Both tests were negative.¹

What Berry actually had was perimenopause. Her estrogen levels were dropping, her vaginal tissue was thinning, and the dryness and inflammation had mimicked an STI closely enough to fool a physician. "My doctor had no knowledge and didn't prepare me," Berry said later, in a conversation with First Lady Jill Biden. The symptoms were textbook. The doctor just didn't have the right textbook.¹

Berry had the best healthcare and top-notch care money can buy. It didn't matter. The system wasn't built to see what was happening to her.

Stephen Heintz of the Rockefeller Brothers Fund once described what he called "acupuncture philanthropy": the idea that philanthropies have only a handful of tiny needles, and the real question is where to insert them to trigger larger systemic change.¹⁹ That question gets especially hard when the system is as complex as healthcare. You can't find acupuncture points by intuition. You have to map the nervous system first.

That's what we did.

In the process, here's what we learned that most people, including many doctors, don't seem to fully grasp about female physiology.

What's Hiding In a Woman's Body

During perimenopause, which can begin in a woman's late thirties and last a decade, estrogen doesn't decline in a smooth curve. It goes haywire. Estradiol levels can spike to double what they were during peak reproductive years, then crash to lower levels than anything previously experienced, sometimes within the same cycle.² The brain floods the system with hormones to compensate. Sometimes the ovaries don't respond. Sometimes they overreact.

This isn't a minor biochemical footnote. Estrogen receptors sit in nearly every organ system: the brain, heart, bones, gut, immune system, liver. When estrogen swings wildly, those systems respond. A perimenopausal woman isn't experiencing one stable physiology. She's a moving target, presenting substantially different metabolic, cardiovascular and neurological profiles depending on where she is in a cycle that has lost its predictability. The same drug, at the same dose, in the same woman, may behave differently depending on where she is in a hormonal cycle that no longer follows a predictable pattern. The science suggests all of this matters for diagnosis and treatment. We don't study it because the system doesn't track it.

The consequences are not abstract. Women are 50% more likely than men to be misdiagnosed after a heart attack.³ Nearly 40% of women seeking care for perimenopause symptoms report feeling misdiagnosed.⁴ Seven of the eight conditions on the standard depression screening scale overlap with perimenopause symptoms, and women of menopausal age use antidepressants more than any other group in the country.⁵

Of 86 FDA-approved drugs studied, 76 showed higher blood concentrations in women. Sex-based differences in how the body processes a drug predicted which sex would experience more adverse reactions 88% of the time.⁶ Ambien was prescribed at the same dose for men and women for twenty years before the FDA discovered women metabolize it 50% more slowly and cut the dose in half.⁷ Only about 4% of drug labels are reported to contain sex-specific dosing information.⁷ The international system for tracking adverse drug reactions doesn't even have a field for menopausal status.⁸

This isn't a niche issue. It affects half the planet's population for decades of their lives, and the system designed to keep them safe literally cannot see it.

We Mapped the System. Here's Where It's Stuck.

My team used big data and advanced computing to model this system, deconstruct it into 881 components across six interconnected industries, and find what's actually holding back progress.⁸ We looked for two things: technology bottlenecks (where a needed capability doesn't exist in sufficient quantity) and behavioral barriers (where the tools exist but something prevents anyone from using them).

The analysis identified over 1,600 distinct factors holding the system back. They split into two categories that tell very different stories.

Technology problems: 158. Behavioral and institutional problems: 854. The ratio is five to one. The system isn't primarily held back by what it can't do. It's held back by what it doesn't bother to do.

Only 18 components in the entire system had neither problem. Eighteen. That's 2%.

Of the 649 components where the technology already exists and works, 635 still had behavioral or institutional barriers preventing it from being used. The tools are built. They sit idle. Hundreds of components are blocked by workflow inertia. Hundreds more by data that simply isn't captured. Over a hundred by guidelines that actively discourage the practice.

The question is why. When we traced how the barriers connect across all six industries, we found they aren't independent problems. They form a single recursive loop.

The Loop

Major clinical guidelines actively tell doctors not to use hormone blood tests to diagnose menopause in women over 45. NICE, the European Society of Endocrinology and the British Menopause Society all say the tests are unreliable for diagnosis because hormone levels fluctuate too wildly during the transition for a single blood draw to be meaningful.⁹ The clinical logic is defensible: symptoms and menstrual history are more reliable than a snapshot of a moving target. The problem is what happens next.

Doctors aren't testing, so they aren't documenting. The Menopause Society found that fewer than one in four symptomatic women had their symptoms recorded in the medical record at all.¹⁰ Among women who actually sought care, only 23% had a menopause-related diagnostic code.¹¹

The data isn't captured, so it doesn't flow downstream. Menopausal status isn't a standard field in drug safety reporting.⁸ The system that catches dangerous drug reactions can't ask whether those reactions are connected to hormonal status, because the upstream data was never recorded.

So the evidence never materializes. Without evidence, the guidelines never change. They say don't test because there's insufficient evidence that testing improves outcomes. There's insufficient evidence because nobody collects the data. Nobody collects the data because the guidelines say don't test.

That's the loop. It has been spinning for decades.

It bigger than menopause.

The Gates Foundation, now led solely by Bill Gates, recently committed $2.5 billion to women's health R&D through 2030, focused on obstetric care, maternal health, gynecological health, contraception and STIs.¹² Separately, Melinda French Gates, who left the Gates Foundation in 2024, committed $1 billion through her own organization Pivotal, including $250 million for women's health and a $100 million partnership with Wellcome Leap targeting cardiovascular disease, autoimmune conditions and mental health.¹³ ¹⁴ Laurene Powell Jobs's Emerson Collective has backed women's health innovations including at-home cervical cancer screening.¹⁵ MacKenzie Scott has distributed over $26 billion to nonprofits since 2019 with health equity as a recurring focus.¹⁶

The largest investments in women's health in philanthropic history are flowing into a system that cannot tell you whether the patient is menopausal.

Consider obstetric care. How do you study whether a drug is safe during pregnancy if you don't track the hormonal environment of the woman taking it? Consider contraception. The next generation of contraceptives will be designed for a female body that the developers cannot fully see changing, because the data systems don't capture the change.

You can pour billions into women's health research, and the results will still flow through a healthcare system that doesn't capture menopausal status more than 75% of the time, that actively discourages hormonal testing in the population most affected by hormonal change, and that is right now dismantling the federal data standards that would make sex-stratified analysis possible. In March 2025, the U.S. government allowed certified EHR systems to skip sex and gender data elements entirely. In December 2025, a proposal would remove them from federal health data standards altogether. HHS defunded the Women's Health Initiative, the largest long-term study of women's health in U.S. history.¹⁷ ¹⁸

At the exact moment when foundations are pouring billions into women's health, the federal government is bricking up the data infrastructure that would make those investments actionable.

The behavioral barriers could begin to move much faster than the technology ones, and that may be the most important thing for a donor to understand. Technology constraints are stubborn by nature: you can't accelerate mouse aging, factory construction takes years, only about half of U.S. hospitals can run third-party guideline software. Of our 158 technology bottlenecks, only one was estimated to resolve in under a year. Most require three to ten years or longer.

The behavioral barriers are different. The tools already exist. What's missing are the processes, the training, the defaults. The studies to produce the evidence that would change the guidelines could start tomorrow.

The cheapest, fastest way to make all of this work is to fix the things nobody thinks of as technology problems.

Fund the definitive trials showing whether outcomes improve when menopause stage is systematically assessed in clinical care, designed with the Menopause Society and ACOG so the results arrive pre-credentialed for guideline adoption. Fund a multi-site collaborative that develops standardized menopause-status intake workflows and trains front-desk and clinical staff. Fund a coalition to push back on the deregulation of sex data capture. Fund the effort to get menopausal status added as a structured field in international drug safety reporting. Fund aged-female-animal breeding colonies so preclinical research can actually study the biology it claims to care about.

Total cost: roughly $50 to $75 million over five to ten years? A little more? A little less? Compare that to the billions now flowing into women's health and it becomes a rounding error.

Not one of those interventions involves funding a new technology. Every single one operates on the institutional infrastructure that determines whether existing technologies get used.

The system isn't primarily held back by what it can't do. It's held back by what it doesn't bother to do.

The Gates Foundation, Pivotal, Wellcome Leap, Emerson Collective, Yield Giving and others have committed historic capital to women's health. The opportunity now is to direct a fraction of that capital toward the institutional plumbing that makes the rest of it work.

That work is not glamorous and money alone won't accomplish it. Changing how doctors document menopause means changing intake workflows, retraining front-desk staff, redesigning EHR defaults, all at the health-system level, one clinic at a time. Getting menopausal status added to international drug safety reports means years of standards body engagement with WHO, EMA and the FDA. Changing guidelines means funding the prospective trials that produce evidence the guideline committees can't ignore, and building relationships with the Menopause Society and ACOG long before the results come in. Countering the policy regression on sex data means building a coalition of clinical societies, patient advocates and EHR vendors who can speak with one voice. This is convening work. Relationship work. The slow, patient, unglamorous work of changing how institutions behave. It's exactly the kind of work that large foundations are uniquely positioned to do, and it's exactly the kind of work that nobody is doing.

Halle Berry's doctor had every tool available to recognize perimenopause. The assays existed. The diagnostic criteria existed. The clinical knowledge existed. What was missing was the institutional expectation that a physician seeing a woman in her fifties with vaginal symptoms should consider hormonal change before reaching for an STI test. Berry spent 72 hours believing she had herpes because no one in the system thought to ask the obvious question.

Seventy-four percent of this value chain already has the technology it needs. The philanthropic "acupuncture" points are identified. The needles are cheap. The system isn't held back by what it can't do. It's held back by what it doesn't bother to do.

That may sound bleak, but it may actually be the most hopeful finding. Raising awareness, building coalitions, funding the right studies, advancing policy reforms: these are things the philanthropic community can start doing today. It's something they're good at. We can indeed move the needle in women's health, at least in this significant part of it, once the hidden bottlenecks stop being invisible. It all starts with being seen.

End Notes

1. Berry's account is drawn from The Drew Barrymore Show, February 24, 2025 (reported by BET and TODAY) and the Day of Unreasonable Conversation summit, March 25, 2024 (reported by The Hollywood Reporter, Good Morning America and PEOPLE). All details are from Berry's own public statements.

2. Hale et al. (2007) and Hale and Burger (2009), as cited in Gordon et al., "Estradiol Fluctuation, Sensitivity to Stress, and Depressive Symptoms in the Menopause Transition," Frontiers in Psychology, 2019.

3. Alabdaljabar et al., "Gender Bias in Diagnosis, Prevention, and Treatment of Cardiovascular Diseases: A Systematic Review," PMC, 2024.

4. Contemporary OB/GYN, "High rates of misdiagnosis reported among perimenopausal women," December 5, 2025.

5. American Journal of Managed Care, "In the Misdiagnosis of Menopause, What Needs to Change?" December 22, 2025.

6. Zucker and Prendergast, "Sex differences in pharmacokinetics predict adverse drug reactions in women," Biology of Sex Differences, 2020.

7. FDA Drug Safety Communication on zolpidem, 2013. The 4% figure: HealthCentral, January 6, 2025.

8. GSV value chain analysis of women's hormonal variation in healthcare, 2026.

9. European Society of Endocrinology, European Journal of Endocrinology, October 2025. NICE guideline NG23, November 2024. British Menopause Society, July 2025.

10. The Menopause Society, October 2, 2024, summarizing a study in Menopause.

11. The Menopause Society, 2025 Annual Meeting abstracts.

12. Gates Foundation, press release, August 4, 2025. The $2.5 billion commitment is from the Gates Foundation (now led by Bill Gates after Melinda French Gates's departure in May 2024). Also: STAT News, August 4, 2025.

13. Pivotal (Melinda French Gates's independent organization, founded 2015), press release, December 10, 2024 ($1 billion commitment). Pivotal and Lever for Change, November 12, 2025 ($250 million Action for Women's Health). Melinda French Gates left the Gates Foundation in May 2024 with $12.5 billion for her own initiatives. Source: GeekWire, November 12, 2025.

14. Wellcome Leap and Pivotal, September 10, 2025 ($100 million partnership).

15. Emerson Collective co-led a $10 million seed round for Teal Health, 2025. CNBC Inside Wealth, February 17, 2026.

16. Panorama Global analysis, February 9, 2026. Philanthropy News Digest, December 11, 2025.

17. ONC/ASTP enforcement discretion, March 21, 2025. ASTP/ONC deregulatory proposal, December 29, 2025.

18. AJMC, "HHS Cuts Funding for NIH-Based Women's Health Initiative," March 2025.

19. Stephen Heintz, Rockefeller Brothers Fund President's Message, 2015: "Philanthropy is like acupuncture: we only have a handful of tiny needles—the question is where to insert them in order to trigger larger systemic change." Also: Chronicle of Philanthropy, October 30, 2025.